ERJ staff report (DS)
St Louis, Missouri -- Solutia Inc., the parent of Flexsys has announced its decision to withdraw from the primary accelerator business. The company is to cease manufacture of these products at its Antwerp facility during the second half of this year. The company said it is working with all affected parties to ensure a smooth transition.
Flexsys range of primary accelerators includes sulphenamides, mercaptos and thiazoles.
Solutia said this decision does not affect the Santoflex PPD manufacturing operations at Antwerp, including production of 4-ADPA, the key intermediate for Solutia's Santoflex(R) line of antidegradants.
Solutia said it made the decision because of fierce price competition notably from Asian suppliers.
This is an external link and should open in a new window. If the window does not appear, please check your pop-up blocking software. ERJ is not responsible for the content of external sites.
Press release from Solutia